STERIS' STE new acquisitions and partnerships strengthen its product offerings. The stock carries a Zacks Rank #2 (Buy) currently. STERIS’ Healthcare segment is gaining from the successful market ...
I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted ...
STERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to ...
STERIS plc’s STE service revenues are driving growth in its Applied Sterilization Technologies (“AST”). The Healthcare segment is gaining from the successful market adoption of its comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results